Humaglobin500 mg/10 ml

Humaglobin is a pooled human plasma-derived immunoglobulin G preparation used for antibody replacement and immunomodulation. Indications vary in strength of evidence:

Established / Approved Uses

• Primary immunodeficiency (PI): Replacement therapy in primary humoral immunodeficiency disorders (e.g., common variable immunodeficiency, X-linked agammaglobulinemia) in adults and children.
• Secondary immunodeficiency: Hypogammaglobulinemia and recurrent bacterial infection associated with chronic lymphocytic leukemia (CLL) or after hematopoietic stem cell transplant.
• Idiopathic thrombocytopenic purpura (ITP): To raise platelet counts rapidly, particularly before surgery or when bleeding risk is significant.
• Kawasaki disease: Used with aspirin to reduce the risk of coronary artery abnormalities.
• Guillain-Barré syndrome (GBS): To hasten neurological recovery in acute severe disease.
• Chronic inflammatory demyelinating polyneuropathy (CIDP): Maintenance therapy to improve neuromuscular function.
• Multifocal motor neuropathy (MMN): Maintenance therapy to improve muscle strength.

Adjunct / Combination Uses

• Kawasaki disease treatment requires concurrent aspirin therapy — Humaglobin alone is not considered adequate.
• Used as an adjunct with corticosteroids or other immunosuppressants in some autoimmune conditions per specialist guidance.

Off-Label Uses (specialist-directed only)

• Certain autoimmune and inflammatory neurological conditions (e.g., myasthenia gravis exacerbation, some autoimmune encephalitides) where guideline or expert-society support exists but formal approval may vary by product and country.

The exact approved indication list can differ between individual Humaglobin brands/products; use only as directed by a qualified physician for a confirmed indication.

Each vial/bottle of Human Immunoglobulin-G [IgG] contains purified immunoglobulin G (predominantly IgG, with trace IgA and IgM) prepared from pooled human plasma from screened donors, processed and virus-inactivated/removed by validated manufacturing steps. Formulations may be supplied as a ready-to-use liquid solution or as a lyophilized (freeze-dried) powder for reconstitution, stabilized with excipients such as glycine, proline, sucrose, or maltose depending on the specific product. Strength is typically expressed as grams of protein (mainly IgG) per volume, e.g., 5% or 10% solutions.

Humaglobin is a biologic (plasma-derived) product containing a broad spectrum of IgG antibodies pooled from thousands of healthy human plasma donors. It provides passive immunity against a wide range of bacterial and viral antigens and also exerts immunomodulatory effects at higher doses, which is the basis for its use in autoimmune and inflammatory disorders.

Humaglobin is administered by a healthcare professional, most commonly by slow intravenous (IV) infusion, though subcutaneous formulations also exist for certain products/indications. It is not an antibiotic and has no direct antimicrobial activity; its benefit in infection-prone patients comes from replacing missing or deficient antibodies.

Humaglobin belongs to the therapeutic class of immune sera and immunoglobulins — specifically, pooled human normal immunoglobulin (IgG) preparations used for passive immunization and immunomodulation.

Mechanism of Action

Human Immunoglobulin-G [IgG] works through two broad mechanisms depending on the dose and indication:

• Replacement therapy (low/standard dose): Supplies a broad repertoire of pre-formed IgG antibodies to patients who lack adequate endogenous antibody production, restoring functional humoral immunity against common pathogens.
• Immunomodulation (high dose): At higher doses used in autoimmune/inflammatory conditions, proposed mechanisms include Fc-receptor blockade on macrophages, modulation of complement activation, neutralization of pathogenic autoantibodies via anti-idiotypic antibodies, downregulation of pro-inflammatory cytokines, and modulation of T-cell and B-cell function.

Pharmacokinetics

After intravenous administration, bioavailability is essentially 100% (subcutaneous absorption is slower and incomplete). The half-life of IgG is approximately 3–4 weeks, though it may be shorter in patients with high catabolism (e.g., during acute inflammatory illness) or in certain immunodeficiency states. Distribution occurs between the intravascular and extravascular compartments, and elimination occurs via normal catabolic pathways of endogenous immunoglobulins.

Humaglobin is administered only by trained healthcare personnel:

• Most commonly given as a slow intravenous (IV) infusion using an infusion pump, with vital signs monitored before, during, and after infusion.
• Some formulations are approved for subcutaneous (SC) infusion, allowing more flexible, sometimes home-based, administration for maintenance therapy in immunodeficiency.
• The infusion rate should start slow and be increased in a stepwise manner only if tolerated, per the specific product's labeling.
• Vials/bottles must reach room temperature before infusion, and product-specific filters/tubing should be used as instructed.

Clinically significant interactions with Humaglobin include:

• Live attenuated vaccines (e.g., measles, mumps, rubella, varicella): Humaglobin can interfere with the immune response to live vaccines. Vaccination should generally be deferred for approximately 3 months (and up to 11 months for some high-dose regimens) after administration, and Humaglobin given after a recent live vaccine may reduce vaccine efficacy — inform the physician of vaccination history.
• Serologic testing interference: Passive transfer of antibodies can lead to misleading positive results on serologic tests (e.g., certain blood group antibody screens, some infectious disease serologies) for a period after administration.
• Nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, other nephrotoxic agents): Concurrent use may add to renal risk; use with caution, especially in patients with other risk factors for renal dysfunction (see Precautions and Warnings).

Adverse effects of Humaglobin range from common, mild infusion-related reactions to rare but serious systemic events.

Common

• Headache, chills, fever, flushing
• Fatigue, malaise
• Nausea, vomiting
• Myalgia, back pain, arthralgia
• Mild hypotension or hypertension during infusion

Serious (uncommon to rare)

• Thrombosis (arterial and venous, including myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism) — a class-wide boxed-warning-level risk.
• Renal dysfunction/acute renal failure, particularly in patients with pre-existing renal impairment, diabetes, volume depletion, or those receiving sucrose-containing formulations.
• Hemolysis (immune-mediated destruction of red blood cells), occasionally severe.
• Aseptic meningitis syndrome (headache, neck stiffness, photophobia, usually resolving within days).
• Anaphylaxis and severe hypersensitivity reactions.
• Transfusion-related acute lung injury (TRALI) — noncardiogenic pulmonary edema.
• Rarely, thrombotic microangiopathy or transmission of infectious agents (minimized by donor screening and viral inactivation steps, but not entirely eliminable).

Report any severe or persistent reaction to a physician immediately, especially during or shortly after infusion.

Pregnancy: Humaglobin has not been studied in adequate, well-controlled trials in pregnant women. As it is a human plasma-derived product, it should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. A physician should be consulted before use in pregnancy.

Lactation: IgG antibodies are naturally present in human milk, and Humaglobin is generally considered compatible with breastfeeding when clinically indicated, but a physician should be consulted to weigh individual risks and benefits before use during breastfeeding.

Boxed-Warning-Level Risks (class-wide for IVIG products)

• Thrombosis: Arterial and venous thrombotic events have occurred with Humaglobin, even in patients without traditional risk factors. Risk increases with advanced age, prolonged immobilization, hyperviscosity, cardiovascular risk factors, and high infusion rates. Use the lowest effective dose and slowest practical infusion rate in at-risk patients, and ensure adequate hydration.
• Renal dysfunction/acute renal failure: Reported particularly with sucrose-stabilized products, especially in patients with pre-existing renal impairment, diabetes mellitus, age over 65, volume depletion, sepsis, or concomitant nephrotoxic drug use. Monitor renal function before and during treatment in at-risk patients, and ensure adequate hydration; avoid rapid infusion rates.
• Hemolysis: Humaglobin can cause immune-mediated hemolysis, sometimes severe; monitor for signs (fatigue, dark urine, jaundice) especially with high cumulative doses and non-O blood groups.

Other Precautions

• Hypersensitivity/anaphylaxis: Monitor closely, especially during the first infusion; have treatment for anaphylaxis available.
• Aseptic meningitis syndrome: More common with high doses and rapid infusion; discontinuation usually leads to resolution without sequelae.
• Hyperproteinemia and hyperviscosity: Use caution in patients with pre-existing hyperviscosity states (e.g., paraproteinemia, cryoglobulinemia).
• Infusion-related reactions: Reduce rate or temporarily stop infusion if reactions occur; premedication (e.g., antihistamines, antipyretics) may be used per physician judgment.
• Because Humaglobin is derived from human plasma, it carries a theoretical, minimized risk of transmitting infectious agents despite donor screening and viral inactivation steps.

Excessive doses or infusion rates of Humaglobin may increase the risk of fluid overload, hyperviscosity, thrombosis, and renal complications, particularly in patients with pre-existing cardiac, renal, or vascular disease. If an overdose or infusion-related emergency is suspected, stop the infusion immediately and seek urgent medical attention or contact emergency services; supportive care should be provided under close medical and hospital supervision. Do not attempt to manage a suspected overdose or severe reaction at home.

Storage requirements vary by specific Humaglobin product and formulation — liquid formulations are commonly stored refrigerated (2–8°C) or at controlled room temperature depending on the brand, while lyophilized powders may have different requirements before and after reconstitution. Always follow the storage instructions on the specific product label. Do not freeze liquid formulations. Protect from light. Keep out of reach of children. Discard any unused portion after opening/reconstitution as directed by the manufacturer.

Renal Impairment

Use Humaglobin with caution in patients with pre-existing renal impairment due to increased risk of acute renal failure (see Precautions and Warnings). Ensure adequate hydration, avoid rapid infusion, and monitor renal function closely.

Hepatic Impairment

No specific dose adjustment guidance is well established for hepatic impairment; use with routine clinical monitoring.

Elderly

Elderly patients, particularly those with reduced renal function or cardiovascular risk factors, are at higher risk for thrombosis and renal complications; use the lowest effective dose and infusion rate.

Pediatric

Humaglobin is used in children for approved indications such as primary immunodeficiency (from age 2 years and older for some products), Kawasaki disease, and ITP, with doses calculated on a weight basis; safety and efficacy for some specific products/indications below certain ages have not been established — follow product-specific pediatric labeling.

Duration varies by indication: replacement therapy for immunodeficiency is typically lifelong, given as repeated infusions every 3–4 weeks (or weekly for subcutaneous regimens) to maintain protective IgG trough levels. For acute conditions such as ITP, Kawasaki disease, or Guillain-Barré syndrome, Humaglobin is usually given as a short course (1–5 days). For CIDP or MMN, maintenance infusions may continue long-term based on ongoing clinical response, as determined by the treating physician.

Lyophilized (freeze-dried) powder formulations of Humaglobin must be reconstituted with the diluent supplied by the manufacturer (commonly sterile water for injection), following the specific volume, gentle mixing technique, and temperature instructions on the product insert to avoid foaming and ensure complete dissolution. Ready-to-use liquid formulations of Humaglobin do not require reconstitution. Always follow the reconstitution instructions specific to the brand/product being used, and administer only via the required in-line filter if specified.

Human Immunoglobulin-G [IgG] is classified as a human plasma-derived immunoglobulin (immune globulin) product, within the broader category of biologic immune sera used for passive immunization and immunomodulation.

Human Immunoglobulin-G [IgG] supplies a broad spectrum of pre-formed IgG antibodies that provide passive immunity against common pathogens (replacement effect) and, at higher doses, modulate the immune system through Fc-receptor blockade, complement modulation, anti-idiotypic neutralization of pathogenic autoantibodies, and cytokine regulation (immunomodulatory effect), which underlies its efficacy in certain autoimmune and inflammatory disorders.

Humaglobin is used in pediatric patients for specific approved indications, including primary immunodeficiency (commonly from 2 years of age and older, depending on the specific product), Kawasaki disease (together with aspirin), and pediatric ITP, with doses calculated by body weight (kg) as for adults. Safety and efficacy in neonates and infants below the studied age range have not been established for most products, and use in this population should be guided by a pediatric specialist. Close monitoring for infusion reactions, renal function, and signs of thrombosis is recommended in children as in adults.